Documentos de Shaw J.E. | REDI

Regresar

Mostrando 3 resultados de: 3

Filtros aplicados

Área temáticas: "Fisiología humana"

Subtipo de publicación

Publisher

Cardiovascular Diabetology(1)

Journal of Clinical Endocrinology and Metabolism(1)

The Lancet Neurology(1)

Área temáticas

Enfermedades(2)

Farmacología y terapéutica(1)

Problemas sociales y servicios a grupos(1)

Área de conocimiento

Medicina interna(2)

Enfermedad cardiovascular(1)

Año de Publicación

Origen

Palabras Claves

Cardiovascular disease(1)

Composite outcome(1)

Geometric mean(1)

Glucagon like peptide-1 receptor agonists(1)

Effect of dulaglutide on cognitive impairment in type 2 diabetes: an exploratory analysis of the REWIND trial

Abstract: Background: Diabetes is an independent risk factor for cognitive impairment. We aimed to investigate

Palabras claves:

Atisso C.M., Basile J.N., Bethel A., Colhoun H.M., Cukierman-Yaffee T., Cushman W.C., DIaz R., Franek E., García-Pérez L.E., Gerstein H.C., Hall S., Keltai M., Lakshmanan M., Lanas F.T., Leiter L.A., PATRICIO LOPEZ -JARAMILLO, Pirags V., Pogosova N., Probstfield J.L., Rao-Melacini P., Raubenheimer P.J., Riddle M.C., Rydén L.E., Shaw J.E., Sheu W.H.H., Temelkova-Kurktschiev T., Xavier D.

Novel Indices of Cognitive Impairment and Incident Cardiovascular Outcomes in the REWIND Trial

Abstract: Context: Low cognitive scores are risk factors for cardiovascular outcomes. Whether this relationshi

Palabras claves:

cardiovascular events, cognitive impairment, Composite outcome, death, Geometric mean, MACE, risk factor, stroke

Angelyn Bethel M., Basile J.N., Cardona-Munoz E.G., Conget I., Cukierman-Yaffee T., Dagenais G.R., Franek E., Gerstein H.C., Hall S., Hâncu N., Jansky P., Lakshmanan M., Lanas F., Leiter L.A., PATRICIO LOPEZ -JARAMILLO, Pirags V., Pogosova N., Probstfield J.L., Ramasundarahettige C., Rao-Melacini P., Raubenheimer P.J., Riddle M.C., Rydén L.E., Shaw J.E., Sheu H.H., Temelkova-Kurktschiev T.

Total cardiovascular or fatal events in people with type 2 diabetes and cardiovascular risk factors treated with dulaglutide in the REWIND trail: a post hoc analysis

Abstract: Background: The Researching cardiovascular Events with a Weekly INcretin in Diabetes (REWIND) double

Palabras claves:

Cardiovascular disease, Glucagon like peptide-1 receptor agonists, Type 2 Diabetes

Atisso C.M., Basile J.N., Colhoun H.M., Conget I., Cushman W.C., Dagenais G.R., Dyal L., Gerstein H.C., Hall S., Keltai M., Lakshmanan M., Lanas F.T., Leiter L.A., Munoz E.G.C., Pais P., PATRICIO LOPEZ -JARAMILLO, Pirags V., Pogosova N., Probstfield J.L., Raubenheimer P.J., Riddle M.C., Rydén L.E., Shaw J.E., Sheu W.H.H., Temelkova-Kurktschiev T.